[Current trends in the treatment of primary glomerulonephritis].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000175:diagnosis / Q000188:drug therapy*; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis
D000305:Adrenal Cortex Hormones; D000925:Anticoagulants; D000970:Antineoplastic Agents; D002699:Chlorambucil; D004176:Dipyridamole; D003520:Cyclophosphamide; D011241:Prednisone
Attuali prospettive di trattamento delle glomerulonefriti primitive.